Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Patients With Multiple Sclerosis

NCT07008378 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT07008378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07008378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Patients With Multiple Sclerosis
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 15, 2025
Completion date
August 31, 2032
Enrollment
60 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis